In the 1980s it became clear that low numbers of primitive hematopoietic cells were present in the peripheral bloodstream. Early clinical trials by investigators in the USA, Australia, and Germany demonstrated that these cells could be collected and reinfused to support highdose chemotherapy procedures in patients otherwise unable to undergo bone marrow collection, usually because of prior pelvic irradiation. It was, however, difficult to obtain adequate numbers of stem cells from patients in the steady state. It was not until the demonstration by Socinski in Boston and Gianni in Milan that these circulating cells were markedly increased following the administration of either cytokines, chemotherapy, or a combination of both that the use of peripheral blood stem cells over bone marrow began to be widely undertaken. Since that time, peripheral blood stem cell collection has become the preferred means of stem cell support for high-dose chemotherapy because of the reduction in time to neutrophil and platelet engraftment, reduction in the number of transfusions and hospital stay, and an apparent reduction in tumor cell contamination.
Background
In the 1980s, Jagannath, Philip, Körbling, and others reported encouraging results following the use of high-dose chemotherapy and autologous bone marrow support in patients with relapsed hematologic malignancies such as Hodgkin's disease, non-Hodgkin's lymphoma, and acute leukemia in second or subsequent remission. [1] [2] [3] This therapy provided durable benefit in 20-40% of such patients, depending on disease burden and sensitivity to pre-transplant chemotherapy. However, mortality rates of 25% were common due to direct damage to lungs, liver, gastrointestinal tract, kidneys, and bladder sustained from the substantial toxicity of drugs such as BCNU, melphalan, etoposide, cisplatin, and cyclophosphamide. Prolonged neutropenia and thrombocytopenia experienced by these patients also Correspondence: Dr TC Shea, University of North Carolina, Division of Medical Oncology, 104 MacNider Building, Campus Box 7305, Chapel Hill, NC 27599, USA contributed to these mortality rates. Shortly after these reports, studies utilizing this same approach in women with metastatic breast cancer also began to appear, but trials in those patients with metastatic disease and chemotherapyresistant tumors yielded poor results. [4] [5] [6] Unless a more effective and less toxic approach could be developed, the excessive morbidity and mortality precluded this treatment in patients who would be most likely to benefit.
Long before the previously mentioned reports, studies by McCarthy, Kurnick, McCredie, Richman, Abrams and others demonstrated the existence of circulating primitive hematopoietic stem cells in normal dogs and other mammals. [7] [8] [9] [10] [11] [12] These peripheral blood progenitor cells (PBPC) appeared to be capable of providing immunologic and hematologic reconstitution to lethally irradiated animals, but their very low quantity made it difficult to safely utilize them for this purpose. Despite these obstacles, investigators such as Stiff and Kessinger in the United States, Juttner and To in Australia, and Körbling in Germany initiated trials utilizing autologous PBPC to rescue patients who had been treated with marrow-ablative or severely myelosuppressive doses of chemotherapy or radiotherapy. [12] [13] [14] [15] [16] [17] [18] These autologous PBPC transplants were generally undertaken either because of prior pelvic irradiation (which made marrow harvesting impossible) or marrow involvement with malignancy (which made marrow harvesting undesirable). Patients treated with PBPC were generally able to achieve eventual hematologic recovery, but a number of patients experienced prolonged thrombocytopenia. It became clear that a higher number of nucleated cells would be required to ensure adequate engraftment compared to the target required when marrow was reinfused. As a result, centers began to use colony-forming units granulocyte-macrophage (CFU-GM) to identify a 'safe' PBPC transplant dose. 19 This represented a more accurate means of identifying the quantity of primitive cells in a PBPC graft, but the assays were labor-intensive and center-dependent, making it difficult to predict marrow recovery following highdose therapy and PBPC infusion. Subsequently, several reports appeared in the literature suggesting that patients infused with less than 1 × 10 5 CFU-GM per kilogram were at greater risk of slow or persistently poor hematopoietic recovery, with thrombocytopenia and anemia being greater problems than neutropenia. 17 While patients receiving more than this number of CFU-GM generally recovered adequate blood counts within 4 weeks of infusion, it often required 10 or more apheresis procedures to obtain this PBPC yield. The cost and morbidity of such a large number of aphereses made this approach less than satisfactory for the majority of patients.
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PBPC mobilization
In the late 1980s, reports by To and Siena indicated that the number of circulating PBPC was greatly increased during the recovery phase following chemotherapy with myelosuppressive, but not myeloablative, agents such as cyclophosphamide. 20, 21 Cytokines such as granulocytemacrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) were also found to markedly increase the number of PBPC, and when chemotherapy and cytokines were combined, a synergistic effect resulting in increased PBPC occurred. 10, [20] [21] [22] [23] [24] These reports suggested that substantially larger numbers of PBPC could now be collected following 'mobilization' with either cytokines, chemotherapy, or a combination of the two. Infusion of these mobilized PBPC following highdose chemotherapy resulted in a marked decrease in the duration of both neutropenia and especially thrombocytopenia compared to the use of marrow alone as an infusion product. [25] [26] [27] [28] [29] When coupled with the administration of postinfusion cytokines, the morbidity and mortality associated with high-dose chemotherapy was markedly reduced. This permitted the application of this approach in patients with less advanced diseases such as high-risk stage II or III breast cancer, first-remission high-risk lymphoma, and acute leukemia, or as part of initial therapy for multiple myeloma. [30] [31] [32] [33] These results have led to the general acceptance of PBPC as the preferred method of hematopoietic support for patients undergoing high-dose chemotherapy and/or irradiation ( Figure 1) . This approach has also been facilitated by the use of the CD34 cell surface marker as a means of identifying the number of primitive cells contained in a PBPC product. 21, 34 The number of infused CD34 + cells has been shown to correlate closely with time to engraftment in patients undergoing intensive chemotherapy or whole body irradiation. While neutrophil engraftment is generally not problematic and will occur with infusion of as few as 1 × cells/kg be infused for sustained neutrophil, platelet, and red blood cell recovery.
34-36
Tumor cell contamination
The advent of this technology has raised a number of important issues. One central theme has been the question of whether this source of stem cells was less likely to be contaminated with tumor cells than marrow from the same donor. In a group of patients with multiple myeloma, Gazitt observed that tumor contamination increased with the frequency of apheresis procedures, suggesting that more rapid mobilization and larger-volume apheresis collections provided a 'cleaner' PBPC infusion product. 37 In women with breast cancer, Ross indicated that tumor cell contamination in PBPC products was less than in marrow from the same individuals, although frequently still present. 38 Brugger reported similar findings in patients with solid tumors, 39 and Billadeau reported the detection of circulating peripheral blood tumor cells in patients with multiple myeloma. 40 While both authors suggest that the peripheral blood may have fewer and, potentially, less clonogenic tumor cells than marrow, they also suggest that sensitive techniques will frequently find evidence of tumor contamination if the PBPC product is screened carefully. While it is likely that PBPC products will contain tumor cells in some percentage of patients, it is also true that the more rapid hematologic engraftment and the potential for tumor cell depletion by CD34 + selection will further increase the utilization of PBPC rather than marrow products for supporting highdose chemotherapy and irradiation.
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Multicycle high-dose chemotherapy
With the rapid hematologic recovery observed with PBPCsupported high-dose chemotherapy, the potential for delivering multiple cycles of these high-dose regimens became apparent. The rationale for this approach is based on the observation that chemotherapy-sensitive tumors (eg Hodgkin's and non-Hodgkin's lymphoma, testis cancer, and limited stage non-small cell lung cancer) all require more than one cycle of therapy to achieve cure. Use of multicycle high-dose chemotherapy was also stimulated by a desire to improve upon the modest success observed in patients with solid tumors such as breast and ovarian cancer. We first confirmed the feasibility of this approach in patients treated with three cycles of single-agent carboplatin at a dose of 1200 mg/m 2 /cycle every 28 days. 43 Patients experienced significantly less neutropenia, thrombocytopenia, febrile days, and days in the hospital, and required fewer red cell and platelet transfusions when chemotherapy was supported by GM-CSF plus PBPC support compared to GM-CSF alone. These patients also had a significantly higher dose intensity and were able to complete all three planned treatment cycles twice as often as patients who did not receive PBPC support. A number of trials have demonstrated this approach to be effective, including those by Gianni in high-risk stage II breast cancer and newly diagnosed non-Hodgkin's lymphoma, and by Crown in patients with breast or ovarian cancer. [44] [45] [46] While comparative trials with single cycles of high-dose chemotherapy are not available, it should be mentioned that at least one trial, that reported by Ayash comparing single-cycle treatment (STAMP V) in women with metastatic breast cancer to sequential therapy (a cycle of high-dose melphalan followed by the STAMP V regimen) failed to demonstrate any benefit from the additional cycle. 47 Further studies are currently underway utilizing this approach in conjunction with carboplatin-, paclitaxel-, and melphalan-based chemotherapy regimens.
PBPC use in allogeneic transplantation
In 1993, Weaver reported the use of G-CSF-mobilized PBPC in four patients undergoing syngeneic transplants. 48 This preceded several reports in 1995 that described the use of PBPC infusions in patients undergoing matched allogeneic transplants. Körbling, Schmitz, and Bensinger all reported earlier platelet and neutrophil recovery in these patients than was observed with allogeneic marrow infusions. [49] [50] [51] These patients also seemed to have less acute graft-versus-host disease (GVHD) and a decreased initial hospital stay and overall morbidity than traditionally observed with marrow transplantation. A more recent report from Storek, however, describes a high incidence of extensive chronic GVHD. 52 Our own experience with 21 PBPC allografts at the University of North Carolina corroborates this high rate of chronic GVHD, as 90% of our patients remain on some form of GVHD therapy more than 18 months after their PBPC transplants. It appears that the infusion of large numbers of peripheral blood T cells in the PBPC transplant is responsible for this phenomenon, underscoring the difference in the etiology and biology of acute vs chronic GVHD.
In an attempt to reduce the incidence of chronic GVHD while still maintaining the antitumor effect of donor T cells, a number of investigators are utilizing CD34 cell selection in their PBPC allografts. [53] [54] [55] This approach maintains the high numbers of CD34 + cells responsible for prompt and early engraftment, while reducing the contaminating T cell population by 2-3 logarithms. Secondary strategies to 'addback' certain T cell subsets at day 30 or later to maintain antitumor effect while avoiding the period of highest risk for acute GVHD are also underway. The success of these 'depletion and add-back' strategies will have a major impact on the utility of allogeneic transplantation in the coming years. The balance between morbidity and mortality associated with GVHD and the beneficial antitumor effect of donor T cells needs to be more carefully defined in the allogeneic setting before PBPC allografts become widely adopted by the transplant community.
Another potential application for allogeneic PBPC lies in their ability to overcome HLA mismatching. This is accomplished by acquisition and infusion of large numbers of primitive hematopoietic cells. Up to a 10-fold greater number of CD34 + cells can be infused during PBPC transplants compared with bone marrow transplants, leading to a reduction in the likelihood of graft rejection in patients who lack a five or six antigen HLA-matched donor. 56 This approach has also been used in HLA-matched unrelated donor transplants with excellent engraftment and no apparent increase in acute GVHD. 57 While this may broaden the potential for performing HLA-mismatched transplants and can reduce the substantial risk of graft rejection experienced by these patients, the ultimate success of this strategy will depend on the severity of GVHD observed and its associated morbidity, mortality, and antitumor effect.
New directions
In addition to the areas of investigation described above, PBPC are also being investigated in gene therapy trials, in which fragments of DNA are being inserted into cells with retroviral or adeno-associated viral vectors (AAV). 58, 59 If a primitive cell with the capacity for self-renewal is infected, then a clone of offspring cells capable of long-term expansion and survival will emerge. If such infected cells are able to express the gene of interest, this system might provide a method for long-term expression of normal cellular or secreted proteins which could replace defective cells lacking an appropriate gene, such as those responsible for defective marrow function in Fanconi's anemia. The major deficiency in this system is the very low numbers of truly primitive hematopoietic stem cells, and the general inefficiency of retrovirally mediated infection of quiescent target cells. This has been further compounded by the realization that efforts to augment cell cycling frequently results in terminal differentiation and loss of self-renewal in primitive hematopoietic cells. 60, 61 How effective the AAV systems will be in avoiding these problems remains to be seen, but these vectors do appear to be less dependent on targeting cycling cells than retrovirally mediated infections. 59 Another area of interest is use of high-dose chemotherapy and PBPC to alter the immune response observed in patients with severe autoimmune disorders such as systemic lupus erythematosis, rheumatoid arthritis, and multiple sclerosis. Occasional anecdotal reports suggest that patients undergoing allogeneic transplants for a malignant condition have been cured of some of these other concurrent conditions. The use of PBPC, especially in the autologous setting where mortality rates of less than 5% are commonly observed, makes this an interesting and exciting area for future investigation. 62 Perhaps the use of intensive chemotherapy will allow the host's immune repertoire to be 'reeducated' and result in an improvement in these debilitating and life-threatening autoimmune diseases.
The use of PBPC to support high-dose chemotherapy and irradiation has led to an explosion of clinical activity for patients with a wide assortment of malignant conditions. Rapid hematopoietic recovery, short hospital stays, and reduction in organ toxicity have reduced mortality and increased the availability of the approach for a large number of patients. The use of high-dose chemotherapy to eliminate bulk disease coupled with improvements in conditioning regimens, the identification and eradication of minimal disease, and non-cross-resistant therapies such as monoclonal antibodies, should improve our treatment of these patients in the years to come.
